rose bengal disodium + anti-PD-1 therapy

This is a **combination therapy** consisting of *rose bengal disodium* (administered as the proprietary intralesional formulation PV-10) and an **anti-PD-1 immune checkpoint inhibitor** (such as pembrolizumab or nivolumab). Rose bengal disodium is a small molecule halogenated xanthene dye that serves as a lysosome-targeting agent capable of inducing immunogenic tumor cell death when administered via intratumoral injection. The dying tumor cells release antigens and damage-associated molecular patterns, which can stimulate antigen-presenting cells and help prime anti-tumor T cell responses. Anti-PD-1 therapies are monoclonal antibodies that block the PD-1 immune checkpoint pathway, thereby enhancing T cell mediated responses against cancer. The combination is being investigated as a means to enhance both direct ablation of injected tumors (by rose bengal disodium) and systemic anti-tumor immune responses (through both agents), with demonstrated augmented efficacy versus single agents in preclinical models and early phase trials in cancers such as metastatic melanoma and uveal melanoma[1][3][5].

Brand names

PV-10PV10PV 10

Other names

rose bengal disodium and anti-PD-1 combination therapy